Researchers from Inserm, CNRS, Sorbonne University and clinicians from the AP-HP and at Paris Brain Institute identified one of the mechanisms explaining ketamine effect as an...
The clinical trial, carried out by a wholly-owned subsidiary of Creso Pharma Limited, Halucenex Life Sciences Inc.,
Revitalist and Wake Network, Inc.
Awakn Life Sciences is expanding its commercial operations into the US through its first licensing partnership with Revitalist Lifestyle and Wellness – one of the largest...
Optimi Health has launched Blue Serenity – Canada’s first natural therapeutic psilocybin product, in collaboration with psilocybin patient advocate Thomas Hartle.
In a move that aims to provide patients in Canada with the “life-changing opportunity” to receive psilocybin-assisted psychotherapy, TheraPsil and Drug Science are collaborating to launch...
B.More has submitted an Investigational New Drug (IND) application for its Psilocybin Alcohol Use Disorder Programme.
Silo Pharma has entered into a commercial evaluation license agreement (CELA) for next-gen liposomes therapeutics to target multiple diseases, including autoimmune disorders.
Ceruvia Lifesciences has submitted an FDA Investigational New Drug (IND) Application for its NYPRG-101 Migraine Prevention Program.
Dimensions has launched its new international plant medicine retreat series in Jamaica.
